US 6,713,509 B1Granted

Controlled release formulation for treating COPD

AssigneeSmithKline Beecham Corporation

InventorsPatrick G. Faulkner, Jaime J. Lucca, Thomas J. Wrzosek

Life of this patent

Estimating the term…

Abstract

This invention relates to a controlled or sustained release formulation designed to deliver a PDE4 inhibitor for treating an inflammatory disease such as asthma or COPD and the like.

Claims4

Dependent claims

A stable controlled release pharmaceutical composition comprising a controlled release excipient, dibasic calcium phosphate, a PDE4-specific inhibitor in an amount of 10 mg and 60 mg, optionally other excipients, and between about 0.5-2.0% weight/weight of water.

Dependencies are inferred from the claim text.

Facts

Application: 09/913,997Filed 22 Aug 2001 · us provisional application
Priority: 23 Feb 1999
Granted: 30 Mar 2004
Term ends: Not estimatedThe source records don’t support an estimate.

Classification6 codes

A61K 31/277
Nitriles; Isonitriles: having a ring, e.g. verapamil
A61K 9/2009
Excipients; Inactive ingredients: inorganic compounds
A61K 9/2018
Organic compounds, e.g. phospholipids, fats: sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
A61K 9/2027
Organic macromolecular compounds: obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, polyacrylates

Family

Application60/121,291Us provisional application · filed 23 Feb 1999
US 6,713,509 B1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results